Skip to content
ASTCT 2022 Fludarabine Shortage Survey
*
1.
How would you describe the current impact of the fludarabine shortage?
(Required.)
Critical
Severe
Moderate
Low
What shortage?
*
2.
Has the fludarabine shortage impacted patient care at your institution?
(Required.)
Yes
No
3.
If yes, please provide an estimate of the number of patients impacted to date.
*
4.
What methods have you implemented to manage the fludarabine shortage? Select all that apply.
(Required.)
Dose batching and rounding
Extended beyond use dating
Patient prioritization/restriction
Use of alternative regimens
Transplant/CAR-T treatment delay
Use of oral fludarabine
Obtaining fludarabine from non-US manufacturers
Other (please specify)
*
5.
Who is primarily responsible for managing the fludarabine shortage at your institution?
(Required.)
Clinical pharmacists
Pharmacy managers
Physicians
Multidisciplinary committee, such as P&T committee or other ad-hoc shortage committee
Other (please specify)
*
6.
If you are prioritizing/restricting fludarabine use to particular patient populations, which are they?
(Required.)
CAR-T patients
RIC or NMA transplant recipients
All allogeneic transplant recipients
Clinical trial patients
Other (please specify)
*
7.
What alternative regimens are you using for CAR-T lymphodepleting chemotherapy (if applicable)? Select all that apply.
(Required.)
Bendamustine
Cyclophosphamide monotherapy
Cyclophosphamide + cladribine
Other (please specify)
*
8.
What alternative regimens are you using for myeloablative conditioning?
(Required.)
Clofarabine + busulfan
Cyclophosphamide + busulfan
Cyclophosphamide + TBI
Etoposide + TBI
Other (please specify)
*
9.
What alternative regimens are you using for reduced-intensity conditioning?
(Required.)
Clofarabine + busulfan
Clofarabine + cyclophosphamide + TBI (haplo)
Pentostatin + cyclophosphamide + TBI
Pentostatin + TBI
Pentostatin + cyclophosphamide + busulfan
Cladribine + melphalan
Cladribine + thiotepa + ATG
Cladribine + busulfan
Other (please specify)